The effects of REG4 expression on chemoresistance of ovarian cancer

References

• Bishnupuri KS, Luo Q, Murmu N, Houchen CW, Anant S, Dieckgraefe BK. 2006. Reg IV activates the epidermal growth factor receptor/Akt/AP-1 signaling pathway in colon adenocarcinomas. Gastroenterology 130:137–149.
   PubMed Web of Science ®Google Scholar
• Bishnupuri KS, Luo Q, Sainathan SK, Kikuchi K, Sureban SM, Sabarinathan M, et al. 2010. Reg IV regulates normal intestinal and colorectal cancer cell susceptibility to radiation-induced apoptosis. Gastroenterology 138:616–626.e1-2.
   PubMed Web of Science ®Google Scholar
• Bishnupuri KS, Sainathan SK, Bishnupuri K, Leahy DR, Luo Q, Anant S, et al. 2014. Reg4-induced mitogenesis involves Akt-GSK3β-β-catenin-TCF-4 signaling in human colorectal cancer. Molecular Carcinogenesis 53(Suppl 1):E169–E180.
   PubMed Web of Science ®Google Scholar
• Bizzarri N, du Bois A, Fruscio R, De Felice F, De Iaco P, Casarin J, et al. 2021. Is there any therapeutic role of pelvic and para-aortic lymphadenectomy in apparent early stage epithelial ovarian cancer? Gynecologic Oncology 160:56–63.
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A; Global Cancer Statistics. 2018. GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians 68:394–424.
   PubMed Web of Science ®Google Scholar
• Chatterjee A, Gupta S. 2018. The multifaceted role of glutathione S-transferases in cancer. Cancer Letters 433:33–42.
   PubMed Web of Science ®Google Scholar
• Cheaib B, Auguste A, Leary A. 2015. The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges. Chinese Journal of Cancer 34:4–16.
   PubMed Web of Science ®Google Scholar
• Chen S, Gou WF, Zhao S, Niu ZF, Zhao Y, Takano Y, Zheng HC. 2015. The role of the REG4 gene and its encoding product in ovarian epithelial carcinoma. BMC Cancer 15:471.
   PubMed Web of Science ®Google Scholar
• Chen Z, Downing S, Tzanakakis ES. 2019. Four decades after the discovery of regenerating islet-derived (Reg) proteins: current understanding and challenges. Frontiers in Cell and Developmental Biology 7:235.
   PubMed Web of Science ®Google Scholar
• Eguchi H, Ishikawa O, Ohigashi H, Takahashi H, Yano M, Nishiyama K, et al. 2009. Serum REG4 level is a predictive biomarker for the response to preoperative chemoradiotherapy in patients with pancreatic cancer. Pancreas 38:791–798.
   PubMed Web of Science ®Google Scholar
• Fagotti A, Ferrandina MG, Vizzielli G, Pasciuto T, Fanfani F, Gallotta V, et al. 2020. Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850). International Journal of Gynecological Cancer 30:1657–1664.
   PubMed Web of Science ®Google Scholar
• Hartupee JC, Zhang H, Bonaldo MF, Soares MB, Dieckgraefe BK. 2001. Isolation and characterization of a cDNA encoding a novel member of the human regenerating protein family: Reg IV. Biochimica et Biophysica Acta 1518:287–293.
   PubMed Web of Science ®Google Scholar
• He HL, Lee YE, Shiue YL, Lee SW, Lin LC, Chen TJ, et al. 2014. Overexpression of REG4 confers an independent negative prognosticator in rectal cancers receiving concurrent chemoradiotherapy. Journal of Surgical Oncology 110:1002–1100.
   PubMed Web of Science ®Google Scholar
• He XJ, Jiang XT, Ma YY, Xia YJ, Wang HJ, Guan TP, et al. 2012. REG4 contributes to the invasiveness of pancreatic cancer by upregulating MMP-7 and MMP-9. Cancer Science 103:2082–2091.
   PubMed Web of Science ®Google Scholar
• Huang J, Zhang L, Greshock J, Colligon TA, Wang Y, Ward R, et al. 2011. Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcome. Genes, Chromosomes & Cancer 50:606–618.
   PubMed Web of Science ®Google Scholar
• Hwang JH, Yoon J, Cho YH, Cha PH, Park JC, Choi KY. 2020. A mutant KRAS-induced factor REG4 promotes cancer stem cell properties via Wnt/β-catenin signaling. International Journal of Cancer 146:2877–2890.
   PubMed Web of Science ®Google Scholar
• Jin J, Lv H, Wu J, Li D, Chen K, Zhang F, et al. 2017. Regenerating family member 4 (Reg4) enhances 5-fluorouracil resistance of gastric cancer through activating MAPK/Erk/Bim signaling pathway. Medical Science Monitor 23:3715–3721.
   PubMed Web of Science ®Google Scholar
• Laganà AS, Colonese F, Colonese E, Sofo V, Salmeri FM, Granese R, et al. 2015. Cytogenetic analysis of epithelial ovarian cancer’s stem cells: an overview on new diagnostic and therapeutic perspectives. European Journal of Gynaecological Oncology 36:495–505.
   PubMed Web of Science ®Google Scholar
• Lehtinen L, Vesterkvist P, Roering P, Korpela T, Hattara L, Kaipio K, et al. 2016. REG4 is highly expressed in mucinous ovarian cancer: a potential novel serum biomarker. PLoS One 11:e0151590.
   PubMed Web of Science ®Google Scholar
• Lheureux S, Braunstein M, Oza AM. 2019. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA: A Cancer Journal for Clinicians 69:280–304.
   PubMed Web of Science ®Google Scholar
• Matsui R, Ferran B, Oh A, Croteau D, Shao D, Han J, et al. 2020. Redox regulation via glutaredoxin-1 and protein S-glutathionylation. Antioxidants & Redox Signaling 32:677–700.
   PubMed Web of Science ®Google Scholar
• Mitani Y, Oue N, Matsumura S, Yoshida K, Noguchi T, Ito M, et al. 2007. Reg IV is a serum biomarker for gastric cancer patients and predicts response to 5-fluorouracil-based chemotherapy. Oncogene 26:4383–4393.
   PubMed Web of Science ®Google Scholar
• Nakayama K, Nakayama N, Kurman RJ, Cope L, Pohl G, Samuels Y, et al. 2006. Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms. Cancer Biology & Therapy 5:779–785.
   PubMed Web of Science ®Google Scholar
• Oue N, Kuniyasu H, Noguchi T, Sentani K, Ito M, Tanaka S, et al. 2007. Serum concentration of Reg IV in patients with colorectal cancer: overexpression and high serum levels of Reg IV are associated with liver metastasis. Oncology 72:371–380.
   PubMed Web of Science ®Google Scholar
• Oue N, Mitani Y, Aung PP, Sakakura C, Takeshima Y, Kaneko M, et al. 2005. Expression and localization of Reg IV in human neoplastic and non-neoplastic tissues: Reg IV expression is associated with intestinal and neuroendocrine differentiation in gastric adenocarcinoma. The Journal of Pathology 207:185–198.
   PubMed Web of Science ®Google Scholar
• Philp AJ, Campbell IG, Leet C, Vincan E, Rockman SP, Whitehead RH, et al. 2001. The phosphatidylinositol 3′-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Research 61:7426–7429.
   PubMed Web of Science ®Google Scholar
• Rafa L, Dessein AF, Devisme L, Buob D, Truant S, Porchet N, et al. 2010. REG4 acts as a mitogenic, motility and pro-invasive factor for colon cancer cells. International Journal of Oncology 36:689–698.
   PubMed Web of Science ®Google Scholar
• Sasaki N, Sachs N, Wiebrands K, Ellenbroek SI, Fumagalli A, Lyubimova A, et al. 2016. Reg4+ deep crypt secretory cells function as epithelial niche for Lgr5+ stem cells in colon. Proceedings of the National Academy of Sciences of the United States of America 113:E5399–E5407.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. 2018. 2019. Cancer statistics. CA: A Cancer Journal for Clinicians 68:7–30.
   PubMed Web of Science ®Google Scholar
• Sun S, Hu Z, Huang S, Ye X, Wang J, Chang J, et al. 2019. REG4 is an indicator for KRAS mutant lung adenocarcinoma with TTF-1 low expression. Journal of Cancer Research and Clinical Oncology 145:2273–2283.
   PubMed Web of Science ®Google Scholar
• Takasawa S. 2016. Regenerating gene (REG) product and its potential clinical usage. Expert Opinion on Therapeutic Targets 20:541–550.
   PubMed Web of Science ®Google Scholar
• Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. 2018. Ovarian cancer statistics. CA: A Cancer Journal for Clinicians 68:284–296.
   PubMed Web of Science ®Google Scholar
• Vitale SG, Capriglione S, Zito G, Lopez S, Gulino FA, Di Guardo F, et al. 2019. Management of endometrial, ovarian and cervical cancer in the elderly: current approach to a challenging condition. Archives of Gynecology and Obstetrics 299:299–315.
   PubMed Web of Science ®Google Scholar
• Wang H, Hu L, Zang M, Zhang B, Duan Y, Fan Z, et al. 2016. REG4 promotes peritoneal metastasis of gastric cancer through GPR37. Oncotarget 7:27874–27888.
   PubMedGoogle Scholar
• Ying LS, Yu JL, Lu XX, Ling ZQ. 2013. Enhanced RegIV expression predicts the intrinsic 5-fluorouracil (5-FU) resistance in advanced gastric cancer. Digestive Diseases and Sciences 58:414–422.
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhu Z, Miao Z, Huang X, Sun Z, Xu H, et al. 2020. The clinical significance and mechanisms of REG4 in human cancers. Frontiers in Oncology 10:559230.
   PubMed Web of Science ®Google Scholar
• Zhang XQ, Yu LT, Du P, Yin TQ, Zhang ZY, Xu Y, et al. 2019. Single-chain antibody against Reg4 suppresses gastric cancer cell growth and enhances 5-FU-induced cell death in vitro. Anti-Cancer Agents in Medicinal Chemistry 19:610–619.
   PubMed Web of Science ®Google Scholar
• Zhao J, Wang J, Wang H, Lai M. 2013. Reg proteins and their roles in inflammation and cancer of the human digestive system. Advances in Clinical Chemistry 61:153–173.
   PubMed Web of Science ®Google Scholar
• Zheng HC. 2017. The molecular mechanisms of chemoresistance in cancers. Oncotarget 8:59950–59964.
   PubMed Web of Science ®Google Scholar
• Zheng HC, Xu XY, Yu M, Takahashi H, Masuda S, Takano Y. 2010. The role of Reg IV gene and its encoding product in gastric carcinogenesis. Human Pathology 41:59–69.
   PubMed Web of Science ®Google Scholar
• Zhou W, Sun M, Wang DL, Wang Y, Jin F, Zhang YY, et al. 2013. Silencing of RegIV by shRNA causes the loss of stemness properties of cancer stem cells in MKN45 gastric cancer cells. Oncology Reports 30:2685–2690.
   PubMed Web of Science ®Google Scholar